Cipher Pharmaceuticals 미래 성장

Future 기준 확인 2/6

Cipher Pharmaceuticals (는) 각각 연간 12.7% 및 18.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 13.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 14.2% 로 예상됩니다.

주요 정보

12.7%

수익 성장률

13.4%

EPS 성장률

Pharmaceuticals 수익 성장	54.3%
매출 성장률	18.8%
향후 자기자본 수익률	14.2%
애널리스트 커버리지	Low
마지막 업데이트	08 Nov 2024

최근 미래 성장 업데이트

Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 09

Recent updates

Cipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You Think

Nov 14

With A 29% Price Drop For Cipher Pharmaceuticals Inc. (TSE:CPH) You'll Still Get What You Pay For

Nov 12

Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 09

There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise

Mar 23

Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)

Mar 22

Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock

May 14

Analysts Just Published A Bright New Outlook For Cipher Pharmaceuticals Inc.'s (TSE:CPH)

May 18

Cipher Pharmaceuticals Inc. Just Missed EPS By 37%: Here's What Analysts Think Will Happen Next

Mar 20

Industry Analysts Just Upgraded Their Cipher Pharmaceuticals Inc. (TSE:CPH) Revenue Forecasts By 12%

Jan 26

수익 및 매출 성장 예측

TSX:CPH - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	55	25	N/A	35	2
12/31/2025	50	23	N/A	26	3
12/31/2024	34	14	N/A	18	3
9/30/2024	26	16	-67	13	N/A
6/30/2024	22	23	17	17	N/A
3/31/2024	22	23	14	14	N/A
12/31/2023	21	20	16	16	N/A
9/30/2023	21	32	15	15	N/A
6/30/2023	20	28	13	13	N/A
3/31/2023	20	27	13	13	N/A
12/31/2022	21	27	11	11	N/A
9/30/2022	22	10	15	15	N/A
6/30/2022	21	8	11	11	N/A
3/31/2022	22	9	11	11	N/A
12/31/2021	22	8	14	14	N/A
9/30/2021	22	5	14	14	N/A
6/30/2021	23	6	12	12	N/A
3/31/2021	21	3	11	11	N/A
12/31/2020	22	4	11	12	N/A
9/30/2020	21	7	7	7	N/A
6/30/2020	22	3	10	11	N/A
3/31/2020	23	4	11	12	N/A
12/31/2019	22	3	7	8	N/A
9/30/2019	23	-1	6	8	N/A
6/30/2019	22	2	4	6	N/A
3/31/2019	23	3	0	2	N/A
12/31/2018	23	1	1	8	N/A
9/30/2018	28	6	7	13	N/A
6/30/2018	34	9	N/A	18	N/A
3/31/2018	37	11	N/A	19	N/A
12/31/2017	40	11	N/A	13	N/A
9/30/2017	34	7	N/A	11	N/A
6/30/2017	32	5	N/A	9	N/A
3/31/2017	31	1	N/A	10	N/A
12/31/2016	30	4	N/A	11	N/A
9/30/2016	33	6	N/A	8	N/A
6/30/2016	34	2	N/A	7	N/A
3/31/2016	34	1	N/A	7	N/A
12/31/2015	34	2	N/A	8	N/A
9/30/2015	32	3	N/A	12	N/A
6/30/2015	30	13	N/A	16	N/A
3/31/2015	30	18	N/A	19	N/A
12/31/2014	29	19	N/A	25	N/A
9/30/2014	33	31	N/A	23	N/A
6/30/2014	32	27	N/A	18	N/A
3/31/2014	29	25	N/A	15	N/A
12/31/2013	25	24	N/A	7	N/A

애널리스트 미래 성장 예측

수입 대 저축률: CPH 의 연간 예상 수익 증가율( 12.7% )이 saving rate( 2.3% 보다 높습니다. ).

수익 vs 시장: CPH 의 연간 수익( 12.7% ) Canadian 시장( 16.5% 보다 느리게 성장할 것으로 예상됩니다. 16.5% 연간).

고성장 수익: CPH 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: CPH 의 수익(연간 18.8% ) Canadian 시장( 7.1% 보다 빠르게 성장할 것으로 예상됩니다. 7.1% 연간).

고성장 수익: CPH 의 수익(연간 18.8% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: CPH 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 14.2 %).

Cipher Pharmaceuticals 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Price target increased by 10% to CA$18.59

Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Price target increased by 7.4% to CA$17.37

Consensus EPS estimates increase by 10%

Consensus revenue estimates increase by 37%

Consensus EPS estimates increase by 53%

Recent updates

Cipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You Think

Investor sentiment deteriorates as stock falls 15%

With A 29% Price Drop For Cipher Pharmaceuticals Inc. (TSE:CPH) You'll Still Get What You Pay For

Price target increased by 10% to CA$18.59

Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Third quarter 2024 earnings: EPS misses analyst expectations

Price target increased by 7.4% to CA$17.37

Cipher Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cipher Pharmaceuticals Inc. Appoints Hamed Ghanei as Chief Business Officer

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improves as stock rises 19%

Consensus EPS estimates increase by 10%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. Announces CFO Changes

Cipher Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024

Consensus revenue estimates increase by 37%

Investor sentiment improves as stock rises 16%

First quarter 2024 earnings released: EPS: US$0.21 (vs US$0.10 in 1Q 2023)

Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024

There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise

Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)

Investor sentiment improves as stock rises 27%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. to Report Q4, 2023 Results on Mar 14, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 15%

Consensus EPS estimates increase by 53%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cipher Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023

Investor sentiment improves as stock rises 15%

Cipher Pharmaceuticals Inc. (TSX:CPH) announces an Equity Buyback for CAD 6 million worth of its shares.

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023

Less than half of directors are independent

Consensus EPS estimates increase by 17%

Consensus revenue estimates decrease by 12%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. to Report Q1, 2023 Results on May 11, 2023

Interim CEO & Chairman of the Board exercised options to buy CA$411k worth of stock.

Interim CEO & Chairman of the Board exercised options to buy CA$462k worth of stock.

Full year 2022 earnings: EPS exceeds analyst expectations

Cipher Pharmaceuticals Inc. Declares Quarterly Dividend, Payable on or About February 28, 2023

Independent Director recently sold CA$61k worth of stock

Price target increased to CA$4.13

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 10, 2022

Second quarter 2022 earnings released: EPS: US$0.08 (vs US$0.10 in 2Q 2021)

Cipher Pharmaceuticals Inc. Announces Appointment of Bryan Jacobs as Chief Financial Officer

Cipher Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 11, 2022

John Mull Decides Not to Stand for Re-Election as Director of Cipher Pharmaceuticals Inc

Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock

First quarter 2022 earnings: EPS exceeds analyst expectations

Cipher Pharmaceuticals Inc. to Report Q1, 2022 Results on May 12, 2022

Price target increased to CA$3.30

Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 22, 2022

Full year 2021 earnings: EPS exceeds analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS US$0.03 (vs US$0.059 in 3Q 2020)

Investor sentiment improved over the past week

Consensus EPS estimates increase to US$0.31

Second quarter 2021 earnings released: EPS US$0.11 (vs US$0.015 in 2Q 2020)

Price target increased to CA$1.82

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Consensus revenue estimates increase to US$21.5m

Analysts Just Published A Bright New Outlook For Cipher Pharmaceuticals Inc.'s (TSE:CPH)